AstriVax Therapeutics is a clinical stage biopharmaceutical company developing DNA-based immunotherapies using a novel platform technology. This patented technology launches self-amplifying live attenuated viral vectors and antigens to elicit vigorous immune responses. The company focuses on creating these immune interventions to treat challenging chronic diseases, with an initial emphasis on human papillomavirus (HPV).
Funding
$30.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many prevalent and emerging viral diseases, such as Hepatitis B and Human Papilloma Virus (HPV), lack effective prophylactic and therapeutic vaccines, posing significant global health challenges. Traditional vaccine development approaches can be slow and may not always elicit a robust and durable immune response.
Solution
AstriVax is developing a novel DNA-based vaccine platform to address challenging diseases. The company's patented technology utilizes self-amplifying live attenuated viral vectors to deliver antigens of interest and stimulate a strong immune response. This "plug & play" platform aims to create both prophylactic and therapeutic vaccines that are more effective against a wide range of viral infectious diseases. The technology is designed to elicit a polyfunctional and vigorous immune response, potentially offering improved protection and treatment options.
Target Audience
The primary target audience includes individuals at risk of contracting Hepatitis B, Human Papilloma Virus (HPV), and other emerging viral infectious diseases, as well as healthcare providers seeking more effective vaccine options.
Features
- Patented DNA-based vaccine platform utilizing self-amplifying live attenuated viral vectors.
- "Plug & Play" design allows for rapid development of vaccines targeting different antigens.
- Designed to elicit a polyfunctional and vigorous immune response.
- Potential application in both prophylactic and therapeutic vaccine settings.